Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 April 2019

Indication(s)



Medicinal product no longer authorised



Silgard is a vaccine for use from the age of 9 years for the prevention of:
– premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types
– genital warts (condyloma acuminata) causally related to specific HPV types.

The use of Silgard should be in accordance with official recommendations.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000732
Orphan designation No
Date First Approved 20-09-2006
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme Ltd